UMB Bank’s Day One Biopharmaceuticals DAWN Stock Holding History

UMB Bank’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3	Closed	–	–	1739
2022 Q3	$0	Buy	+3	New	+$64	﹤0.01%	1796

Other funds holding DAWN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CPX

Canaan Partners XI Menlo Park, California $127M AUM 217.49% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

UMB Bank's DAWN Position: Q4 2022 in Review

UMB Bank sold out of Day One Biopharmaceuticals (DAWN) in Q4 2022, closing a stake of 3 shares.

UMB Bank first reported a position in DAWN in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 109 funds tracked by Wall St. Rank hold DAWN as of Q4 2022.

UMB Bank reported no remaining Day One Biopharmaceuticals position as of Q4 2022 after selling out during the quarter.
UMB Bank sold 3 Day One Biopharmaceuticals shares in Q4 2022.
UMB Bank first reported a position in Day One Biopharmaceuticals in Q3 2022 and held it in 1 quarter.
UMB Bank's Day One Biopharmaceuticals position peaked at $0 in Q3 2022.
109 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q4 2022.

Based on UMB Bank's 13F filing for Q4 2022, filed 10 Jan 2023.